Overview Request Sample Pages Request Customization Download PDF
You are viewing: Japan Preimplantation Genetic Testing Market analysis

The Japan Preimplantation Genetic Testing Market was valued at $24 Million in 2025 and projected to reach to $42.3 Million by 2030, representing a compound annual growth rate of 12.1%. Japan's Preimplantation Genetic Testing market is positioned for sustained expansion driven by demographic pressures and technological advancement.

Japan Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Preimplantation Genetic Testing Market Trends and Insights

  • This 12.1% compound annual growth rate reflects Japan's advancing reproductive healthcare infrastructure and increasing adoption of genetic screening technologies among fertility clinics.
  • Japan's aging population and declining birth rates have intensified demand for assisted reproductive technologies, positioning PGT as a critical component of fertility treatment protocols. The Japanese market benefits from strong regulatory frameworks, high healthcare spending, and growing patient awareness regarding genetic disorders.
  • Japan's emphasis on precision medicine and technological innovation has accelerated PGT adoption across major metropolitan centers and specialized fertility centers.
  • Between 2025 and 2030, Japan is expected to see expanded clinical applications, improved reimbursement pathways, and enhanced accessibility to PGT services, driving sustained market expansion throughout the forecast period..

Key Market Statistics

  • CAGR (2025-2030) 12.1% CAGR
  • Market Size, 2025 ~USD 24 Million
  • Forecast, 2030 ~USD 42.3 Million
  • Country Japan

Japan Preimplantation Genetic Testing Market Overview

Market Valuation & Growth :

Japan's PGT market is valued at $24.0 million in 2025, with a robust 12.1% CAGR projected through 2030, reaching $42.3 million. This growth rate exceeds the global average of 10.5%, indicating Japan's accelerating adoption of genetic testing technologies.

Demographic Drivers :

Japan's aging population and declining birth rates are creating heightened demand for advanced reproductive technologies. Couples are increasingly seeking PGT services to optimize fertility outcomes and reduce genetic risks, driving market expansion across major metropolitan areas.

Healthcare Infrastructure Advancement :

Japan's fertility clinics are rapidly modernizing with state-of-the-art genetic screening capabilities. Enhanced regulatory frameworks and increased investment in reproductive medicine infrastructure are facilitating wider PGT adoption among healthcare providers nationwide.

Rising Consumer Awareness :

Growing public awareness of genetic screening benefits and improved accessibility to PGT services in Japan are expanding the patient base. Educational initiatives and media coverage are normalizing genetic testing as a standard component of assisted reproductive technology protocols.

Japan Preimplantation Genetic Testing Market Dynamics

  • The nation's aging society and persistently low birth rates are compelling prospective parents to seek advanced reproductive solutions, with PGT becoming increasingly integrated into fertility treatment protocols.
  • Healthcare providers are investing significantly in genetic testing infrastructure to meet rising demand. Looking ahead to 2030, Japan's PGT market will benefit from continued regulatory support, enhanced reimbursement policies, and growing clinical acceptance.
  • The convergence of demographic necessity, technological innovation, and improved healthcare accessibility will solidify Japan as a key growth market within Asia's reproductive genetics sector, with sustained double-digit growth anticipated throughout the forecast period..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Japan's PGT market is valued at $24.0 million in 2025 and will reach $42.3 million by 2030, representing a 12.1% CAGR.
      • Japan's aging demographics and declining birth rates are driving increased demand for advanced reproductive technologies including PGT.
      • Japan's robust healthcare infrastructure and regulatory environment support rapid adoption and expansion of genetic testing services.
      • Between 2025 and 2030, Japan expects improved reimbursement policies and wider clinical accessibility to accelerate market growth.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Japan Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES6.16.77.48.29.210.411.713.312.5
      FERTILITY CLINICS17.418.920.823.125.728.832.336.411.9
      HOSPITALS4.44.75.15.66.26.97.78.510.8
      OTHER END USERS1.71.822.12.42.62.93.210.1
      TOTAL29.532.135.239.143.548.754.661.411.7

      Target Audience

      • Fertility Clinic Operators : Japanese fertility clinics need market intelligence to optimize PGT service offerings, benchmark against competitors, and plan capital investments in genetic testing infrastructure to capture growing patient demand.
      • Genetic Testing Service Providers : Diagnostic companies and laboratory operators require Japan-specific market data to identify expansion opportunities, understand clinical adoption rates, and develop localized service delivery models for the Japanese market.
      • Medical Device & Technology Vendors : Equipment manufacturers and software developers need insights into Japan's PGT technology preferences, regulatory requirements, and procurement patterns to position products effectively within Japanese fertility clinics.
      • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Japan's reproductive healthcare sector require detailed market sizing, growth projections, and competitive dynamics to assess portfolio companies and acquisition targets.
      • Healthcare Policy & Government Bodies : Japanese health ministry officials and policy makers need market research to inform reimbursement policies, regulatory frameworks, and public health initiatives supporting reproductive genetics accessibility and affordability.

      Key Companies in the Japan Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market-Specific Growth Intelligence : Gain detailed insights into Japan's 12.1% CAGR trajectory and understand the unique demographic and healthcare factors driving market expansion from $24.0M to $42.3M through 2030.
      • Competitive Landscape Analysis : Identify key players, market consolidation trends, and competitive positioning strategies specific to Japan's fertility clinic ecosystem and genetic testing service providers.
      • Regulatory & Reimbursement Insights : Access Japan-specific regulatory frameworks, insurance coverage policies, and government incentives shaping PGT adoption and market dynamics in the Japanese healthcare system.
      • Clinical Adoption Patterns : Understand how Japanese fertility clinics are integrating PGT into treatment protocols, including technology preferences, testing methodologies, and patient demographic profiles driving demand.
      • Strategic Market Entry Planning : Develop informed market entry strategies with Japan-specific data on distribution channels, partnership opportunities, pricing models, and growth acceleration pathways for new market entrants.

      Frequently asked questions

      What is the current market size of PGT in Japan?

      Japan's Preimplantation Genetic Testing market was valued at $24.0 million in 2025 and is projected to grow to $42.3 million by 2030.

      What is the expected growth rate for Japan's PGT market?

      Japan's PGT market is expected to grow at a compound annual growth rate (CAGR) of 12.1% from 2025 to 2030.

      What factors are driving PGT adoption in Japan?

      Japan's aging population, declining birth rates, advanced healthcare infrastructure, and increasing patient awareness of genetic disorders are primary drivers of PGT market growth.

      How does Japan's PGT market compare to global trends?

      Japan's 12.1% CAGR exceeds the global average of 10.5%, indicating faster market expansion and higher adoption rates in Japan compared to worldwide trends.

      What regulatory environment supports PGT in Japan?

      Japan maintains strong regulatory frameworks and high healthcare spending standards that facilitate PGT service expansion and support clinical adoption across fertility centers.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status